Test Price
2,800 AED✅ Home Collection Available
SCN4A Gene Hyperkalemic Periodic Paralysis Genetic Test in UAE | 2800 AED
Executive Summary & Core Metrics
Executive Summary
- ✓ 99.9% Diagnostic Sensitivity – ISO 9001:2015 accredited NGS processing ensures ultra‑reliable variant detection.
- ✓ Premium Home Collection – Paid hospital‑grade mobile phlebotomy with cold‑chain logistics (8 AM – 11 PM).
- ✓ Post‑Test Clinical Guidance – Telephonic interpretation session with a neurologist to explain results and next steps.
- ✓ Insurance Made Easy – Direct billing verification via WhatsApp +971 54 548 8731.
Report in
3-4 Weeks
Price
2800 AED
Test Overview & Methodology
The SCN4A gene test uses next‑generation sequencing to identify pathogenic variants responsible for hyperkalemic periodic paralysis, a sodium channelopathy causing episodic muscle weakness. This single‑gene NGS analysis delivers a definitive molecular diagnosis, guiding precision neurology and family risk assessment.
| Feature | Our SCN4A NGS Test | Closest Alternative (Sanger Sequencing) |
|---|---|---|
| Methodology | Next‑Generation Sequencing | Sanger Sequencing (exon‑by‑exon) |
| Turnaround | 3-4 Weeks | 6-8 Weeks |
| Coverage | Full coding + splice sites | Targeted exons only |
| Sensitivity | 99.9% variant detection | ~95% |
| Cost (AED) | 2800 | 2500–3000 |
Physician Insight & Safety Protocols
Clinical Note from Lina Osama Zaki Quteineh – Consultant Medical Genetics, DHA License 9294403
As a medical geneticist, I understand the anxiety that accompanies episodic paralysis. Genetic testing offers precise answers but must be contextualized within your full clinical picture and family history. A positive SCN4A variant confirms the diagnosis and opens doors to targeted management. A negative result does not rule out the condition if symptoms persist. Use this report as a tool for informed decision‑making, never as the sole determinant of your care.
Medication Advisory – Do Not Discontinue Prescribed Therapy
⚠ Medication Warning
Do not discontinue prescribed medication (e.g., acetazolamide, potassium‑modifying drugs) without consulting your physician. Abrupt changes may provoke severe paralysis or cardiac arrhythmia.
Exclusion Criteria – Do Not Proceed with Collection If
- Patient is under 18 and lacks a legal guardian’s informed consent (UAE Federal Decree‑Law No. 4 of 2016 on Medical Liability).
- Individual unable to provide valid informed consent due to cognitive impairment or language barrier without an authorized interpreter.
- Sample type other than whole blood, extracted DNA, or FTA card; saliva or buccal swab not validated for this assay.
- Acute haemolytic crisis or recent blood transfusion within 2 weeks (may interfere with DNA quality).
Patient FAQ & Clinical Guidance
1. What does a positive SCN4A variant mean?
A positive SCN4A variant confirms a genetic diagnosis of hyperkalemic periodic paralysis, enabling targeted management. It allows your neurologist to tailor preventive strategies—such as diet modifications, carbohydrate loading, and medication—and inform family members about their own risk.
2. How is the test performed and what sample is required?
A simple blood sample or extracted DNA is analysed by next‑generation sequencing for precise SCN4A variants. We accept whole blood (3‑5 mL in EDTA tube), extracted DNA, or a dried blood spot on an FTA card. Home collection is available throughout the UAE with strict cold‑chain handling.
3. Do I need genetic counselling before the test?
Pre‑test genetic counselling is strongly recommended to interpret results, assess family risk, and ensure informed decisions. A certified genetic counsellor will construct a pedigree, explain autosomal dominant inheritance, and discuss potential outcomes before sample collection. We can arrange a tele‑counselling session within 48h.
UAE Regulatory & Data Privacy Adherence
Regulatory Compliance & Data Privacy
This test is performed under UAE Federal Decree‑Law No. 4 of 2016 on Medical Liability. All personal genetic data is processed in strict accordance with Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Laboratory services are accredited to ISO 9001:2015 (Cert: INT/EGQ/2509DA/3139) with DHA‑compliant facility license 1143.
Clinical & Logistical Metadata
| Test Name | SCN4A Gene Hyperkalemic Periodic Paralysis Genetic Test |
| Price (AED) | 2,800 |
| Turnaround Time | 3-4 Weeks |
| Sample Type / Matrix | Whole Blood (EDTA), Extracted DNA, or Dried Blood Spot (FTA Card) |
| Methodology Used | Next‑Generation Sequencing (NGS) – Full gene sequencing including coding regions and splice sites |
| ICD-10-CM Code | G72.3 – Periodic paralysis |
| LOINC Code | 81265-8 – SCN4A gene full sequencing |
| DHA Facility License & Laboratory Address | DHA License: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | Corporate Lab: DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians